

and grocery items in supermarkets, or narrower product markets contained therein, in the "New Orleans metro area," which consists of the parishes of Orleans, Jefferson, and St. Bernard, or narrower geographic markets contained therein. According to the draft complaints, the relevant markets are highly concentrated and entry is difficult or unlikely. Schwegmann's acquisition of National may reduce competition in these markets by eliminating the direct competition between Schwegmann and National, by increasing the likelihood that Schwegmann will become a dominant firm, and by increasing the likelihood of collusive behavior among the remaining competitors.

The agreement containing consent order attempts to remedy the Commission's competitive concerns about the acquisition. Under the terms of the proposed order, Schwegmann must divest seven supermarkets within twelve months, to a purchaser approved by the Commission. If Schwegmann fails to satisfy the divestiture provisions, the Commission may appoint a trustee to divest supermarkets to satisfy the terms of the order. The seven supermarkets to be divested are:

1. That Stanley supermarket located at 315 E. Judge Perez Drive (store No. 79), Chalmette, LA;
2. Canal Villere supermarket located at 4726 Paris Avenue (store No. 24), New Orleans, LA;
3. Canal Villere supermarket located at 2125 Caton Street (store No. 25), New Orleans, LA;
4. That Stanley supermarket located at 4223 Chef Menteur Highway (store No. 8), New Orleans, LA;
5. That Stanley supermarket located at 9319 Jefferson Highway (store No. 33), River Ridge, LA;
6. Canal Villere supermarket located at 5245 Veterans Memorial Boulevard (store No. 93), Metairie, LA;
7. Canal Villere supermarket located at 135 Robert E. Lee Boulevard (store No. 83), New Orleans, LA.

For a period of ten years from the date the order becomes final, the order also prohibits Schwegmann from acquiring, without prior Commission approval, supermarket assets located in, or any interest (such as stock) in any entity that owns or operates a supermarket located in, the New Orleans metro area. This does not prevent Schwegmann from constructing new supermarket facilities on its own; nor does it prevent Schwegmann from leasing facilities not operated as supermarkets within the previous six months.

For a period of ten years, if Schwegmann sells or leases a

supermarket to another person, Schwegmann may not enter into or enforce any agreement that would restrict the ability of that person to operate a supermarket. In addition, subject to certain exceptions, Schwegmann may not remove any equipment from a supermarket it owns or operates prior to a sale, sublease, assignment, or change in occupancy.

The respondent is required to provide to the Commission a report of compliance with the order within sixty (60) days following the date the order becomes final, every sixty (60) days thereafter until the divestitures are completed, and annually for a period of ten years.

The purpose of this analysis is to invite public comment on the proposed consent order to aid the Commission in its determination of whether it should make final the proposed consent order contained in the agreement.

This analysis is not intended to constitute an official interpretation of the agreement and proposed consent order, nor is it intended to modify the terms of the agreement and proposed consent order in any way.

**Donald S. Clark,**  
*Secretary.*

**Concurring Statement of Commissioner Mary L. Azcuenaga**

Re: *Schnuck Markets, Inc.*, File No. 941-0131; *Schwegmann Giant Super Markets, Inc.*, File No. 941-0130

The two complaints allege geographic markets comprising "the St. Louis MSA, and narrower markets contained therein" and "metro New Orleans, Louisiana area, which consists of the parishes of Orleans, Jefferson, and St. Bernard, and narrower markets contained therein." Although I question the broad geographic markets alleged, the investigational record contains sufficient information to support a finding of reason to believe with respect to small, discrete geographic markets located within the broad regions alleged in the complaint, and the stores to be divested were selected with a view to remedying competitive concerns in the small, discrete markets.

In addition, the complaints allege as the product market "the retail sale of food and grocery products in supermarkets, and narrower markets contained therein." A serious argument can be made that the market should include sales of food and groceries in certain stores other than traditional supermarkets. Since the investigational record suggests that the concentration is high even if additional sales are included in the market, the issue need

not be resolved at this time. Accordingly, I concur in the decision to accept the consent agreements for publication.

[FR Doc. 95-6343 Filed 3-14-95; 8:45 am]

BILLING CODE 6750-01-M

**GENERAL SERVICES ADMINISTRATION**

**Construction of FDA Regional Office and Laboratory; Environmental Impact Statement; Jamaica, Queens County, New York**

**AGENCY:** General Services Administration (GSA).

**ACTION:** Notice of Intent to hold a public scoping meeting and prepare and file an Environmental Impact Statement (EIS).

**SUMMARY:** The GSA is issuing this notice to advise the public that an EIS will be prepared for the construction of the FDA Regional Office and Laboratory in Jamaica, Queens County, New York.

**FOR FURTHER INFORMATION CONTACT:** Mr. Peter A. Sneed, Asset Manager, U.S. General Services Administration, Public Buildings Service, 26 Federal Plaza, Room 1609, New York City, NY 10278, (212) 264-3581.

**SUPPLEMENTARY INFORMATION:** The GSA will serve as lead agency and project sponsor in the preparation and filing of an EIS for the construction of the FDA Regional Office and Laboratory in Jamaica, Queens County, New York. The proposed action would involve the construction and operation of the facility on an assemblage of two properties located at the intersection 158th Street and Liberty Avenue. Combined, these two properties are 4.25 acres (1.73 hectares) in size. The existing FDA regional facilities are located in Federal Building #2 of the Federal Complex in Sunset Park, Brooklyn, New York. Due to the deteriorated condition of, and space constraints in, the present facility, FDA has requested relocation to a modern expanded facility to accommodate the additional staffing required to provide increased oversight and product monitoring. This action is intended to provide 175,000 occupiable square feet (16,250 square meters) of office, storage, and special space.

The EIS will evaluate the FDA regional facility alternatives, including the No-Action Alternative. It will also evaluate impacts on the affected environment, including, but not limited to, socioeconomics, hazardous materials, traffic/transportation, land use, cultural resources, and noise.

**PUBLIC SCOPING MEETING:** To ensure that all issues relating to the proposed project are identified and all potentially significant issues are addressed and satisfied in the EIS, public comments and suggestions are being solicited. To facilitate the receipt of comments, a public scoping meeting will be held on Monday, March 20, 1995 from 2 p.m. to 4 p.m. and from 6 p.m. to 8 p.m. in the auditorium of the Joseph Addabbo Federal Building, 1 Jamaica Center Plaza, Jamaica, New York.

Written comments may be mailed to the informational contact person no later than April 7, 1995.

Issued in New York City, New York on March 7, 1995.

**Karen R. Adler,**

*Regional Administrator, General Services Administration, Region 2.*

[FR Doc. 95-6289 Filed 3-14-95; 8:45 am]

BILLING CODE 6820-23-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Toxic Substances and Disease Registry

#### Board of Scientific Counselors, Agency for Toxic Substances and Disease Registry: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Agency for Toxic Substances and Disease Registry (ATSDR) announces the following committee meeting.

*Name:* Board of Scientific Counselors, ATSDR.

*Times and dates:* 8:30 a.m.-5:00 p.m., April 20, 1995. 8:30 a.m.-12:40 p.m., April 21, 1995.

*Place:* The Centers for Disease Control and Prevention, Auditorium A, 1600 Clifton Road, NE, Atlanta, Georgia 30333.

*Status:* The entire meeting will be open to the public.

*Purpose:* The Board of Scientific Counselors, ATSDR, advises the Administrator, ATSDR, on ATSDR programs to ensure scientific quality, timeliness, utility, and dissemination of results. Specifically, the Board advises on the adequacy of the science in ATSDR-supported research, emerging problems that require scientific investigation, accuracy and currency of the science in ATSDR reports, and program areas to emphasize and/or to de-emphasize.

*Agenda:* The Agenda will include an update on Superfund reauthorization and will also focus on other issues of concern to ATSDR, including ATSDR's programs for physician and community education, development of the medical assistance program, progress report by the Board of Scientific Counselors, ATSDR, work group on health studies, and an overview of the

ATSDR Great Lakes Human Health Effects Research Program.

Written comments are welcome and should be received by the contract person listed below prior to the opening of the meeting.

*Contact person for more information:* Charles Xintaras, Sc.D., Executive Secretary, Board of Scientific Counselors, ATSDR, Mailstop E-28, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone 404/639-0708.

Dated: March 8, 1995.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 95-6318 Filed 3-14-95; 8:45 am]

BILLING CODE 4163-70-M

### National Institutes of Health Genome Research Review Committee; Notice of Cancellation of Meeting

Notice is hereby given of the cancellation of the meeting of the Genome Research Review Committee, National Center for Human Genome Research, March 14, 1995, Embassy Suites Hotel, Chevy Chase Pavilion, Washington, D.C. which was published in the Federal Register on March 3, 1995 (60 FR 11975).

The meeting was cancelled due to complications of other commitments of several members of the committee and will be rescheduled at a later date.

Dated: March 9, 1995.

**Margery G. Grubb,**

*Senior Committee Management Specialist, NIH.*

[FR Doc. 95-6326 Filed 3-14-95; 8:45 am]

BILLING CODE 4140-01-M

### National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Review of the Vascular Disease Academic Award.

*Date:* April 9-10, 1995.

*Time:* 7 p.m.

*Place:* Holiday Inn, Chevy Chase, Maryland.

*Contact Person:* S. Charles Selden, Ph.D., 5333 Westbard Avenue, Room 552, Bethesda, Maryland 20892, (301) 594-7476.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial

property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 9, 1995.

**Margery G. Grubb,**

*Senior Committee Management Specialist, NIH.*

[FR Doc. 95-6398 Filed 3-14-95; 8:45 am]

BILLING CODE 4140-01-M

### National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Mechanisms of Post Bone Marrow Transplantation Lung Injury.

*Date:* April 5-6, 1995.

*Time:* 7:30 p.m.

*Place:* Holiday Inn, Chevy Chase, Maryland.

*Contact Person:* Dr. Lynn M. Amende, 5333 Westbard Avenue, Room 5A10, Bethesda, Maryland 20892, (301) 594-7480.

*Purpose/Agenda:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: March 9, 1995.

**Margery G. Grubb,**

*Senior Committee Management Specialist, NIH.*

[FR Doc. 95-6397 Filed 3-14-95; 8:45 am]

BILLING CODE 4140-01-M